International Stem Cell (ISCO) Current Leases (2019 - 2026)
International Stem Cell (ISCO) posted quarterly Current Leases of $393000.0 for Q4 2025, up 19.09% year-over-year from $330000.0 in Q4 2024, and up 2.61% quarter-over-quarter from $383000.0 in Q3 2025.
International Stem Cell (ISCO) Current Leases (2019 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Current Leases for 7 consecutive years, with $393000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Leases rose 19.09% year-over-year to $393000.0; the TTM figure through Dec 2025 stood at $393000.0 (up 19.09% YoY), while the FY2025 annual figure was $393000.0, up 19.09% from the prior year.
- Current Leases grew to $393000.0 in Q4 2025 per ISCO's latest filing, from $383000.0 in the prior quarter.
- Across five years, Current Leases topped out at $393000.0 in Q4 2025 and bottomed at $179000.0 in Q4 2021.
- Historically, Current Leases has averaged $286800.0 across 5 years, with a median of $290000.0 in 2021.
- Annual changes were most pronounced in 2021 — Current Leases plunged 48.27% — and 2022, when it gained 28.49%.
- International Stem Cell's Current Leases stood at $179000.0 in 2021, then gained by 28.49% to $230000.0 in 2022, then rose by 20.0% to $276000.0 in 2023, then increased by 19.57% to $330000.0 in 2024, then rose by 19.09% to $393000.0 in 2025.
- Business Quant data shows ISCO's Current Leases at $393000.0 in Q4 2025, $383000.0 in Q3 2025, and $371000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn | 199,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 383,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | 361,000.00 |
| Dec 31, 2024 | 330,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 302,000.00 |
| Mar 31, 2024 | 288,000.00 |
| Dec 31, 2023 | 276,000.00 |
| Sep 30, 2023 | 263,000.00 |
| Jun 30, 2023 | 252,000.00 |
| Mar 31, 2023 | 241,000.00 |
| Dec 31, 2022 | 230,000.00 |
| Sep 30, 2022 | 219,000.00 |
| Jun 30, 2022 | 208,000.00 |
| Mar 31, 2022 | 196,000.00 |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2021 | 292,000.00 |
| Jun 30, 2021 | 309,000.00 |